1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Orange Corners South Africa and AstraZeneca South Africa join forces in a new partnership to bolster support for young entrepreneurs Partnership aims to support young entrepreneurs, nurture local talent, and boost inclusive economic progress in South Africa

01/25/2022 | 03:44am EDT

Earlier today, Orange Corners South Africa (OC) and AstraZeneca (AstraZeneca.com)South Africa officially announced a new partnership to support Orange Corner’s programme in South Africa focused on creating an enabling environment for young entrepreneurs.

The Orange Corners (OC) programme is an initiative of the Ministry of Foreign Affairs of the Netherlands in collaboration with Dutch companies. In South Africa, OC collaborates with companies such as Vopak, Heineken and Philips. OC supports young entrepreneurs to turn innovative ideas and start-ups into thriving businesses. Orange Corners is committed to contributing to inclusive economic growth and employment creation. The programme provides tailor made support to both grassroots and more advanced entrepreneurs through one-on-one business development coaching, which aims to close the gaps in their individual business development plans as set out at the beginning of the OC journey. The coaching is complemented with training, masterclasses, access to markets and, to a limited extent, working capital needs.

Orange Corners is very pleased to welcome AstraZeneca as a private partner in South Africa. As part of the collaboration, AstraZeneca will provide funding to the programme through its Young Health Programme (YHP), a holistic and integrated community investment programme focused on connecting adolescents to health and wellbeing. AstraZeneca will also participate in OC’s mentorship programme, offering support for young entrepreneurs.

Barbara Nel, Country President African Cluster (SA, SSA, FSA) at AstraZeneca, said:

"This partnership with Orange Corners South Africa is integral to our unwavering commitment to create sustainable impact in Africa. We want to ensure that young entrepreneurs in South Africa have a supportive platform and inclusive opportunities, with access to a network of expertise and experience, helping them to develop their innovative ideas into thriving businesses. We recognise that making a meaningful difference in the communities in which we work and live, requires strong collaboration and partnering with like-minded organisations such as Orange Corners, who are equally committed to making change happen. We are looking forward to working together to accelerate African entrepreneurial capacity."

Han Peters, the Dutch ambassador to South Africa, said:

"Entrepreneurship plays a key role in solving social economic challenges. We are committed to making a positive contribution to South Africa by creating an enabling environment for entrepreneurs - a key element of which is to link startups to companies and knowledge institutes. This is not possible without partnerships, so we are excited about the collaboration with AstraZeneca. It will allow Orange Corners to assist more entrepreneurs, create more jobs and most importantly, make a tangible difference in the day-to-day lives of individuals."

Distributed by APO Group on behalf of AstraZeneca.

Email: info@orangecorners.com

Email: iris.sauer@rvo.nl and Evi.Hyde@astrazeneca.com

Orange Corners
Orange Corners is managed by the Netherlands Enterprise Agency at the request of the Dutch Ministry of Foreign Affairs. Each Orange Corner is initiated by a local Dutch Embassy and in close corporation with local partners. Orange Corners aims to increase job prospects for youth, through building ecosystems for young entrepreneurship and youth employment. The scope is youth between the ages of 18 to 35 in Sub Sahara, Africa and the Middle East.

Orange Corners South Africa is an initiative of the Dutch Embassy in Pretoria, with special thanks to implementing partner Signature Support.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit AstraZeneca.com and follow the Company on LinkedIn https://bit.ly/3fTmnV4.

© African Press Organization, source Press Releases

All news about ASTRAZENECA PLC
09:22aAstraZeneca Doses First Patients in Phase-III Trial Evaluating Anifrolumab in Kidney In..
09:03aFirst Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
08:18aASTRAZENECA : Berenberg keeps its Buy rating
05/26Cancer treatments may benefit from lessons of pandemic set-backs -AstraZeneca executive
05/25ASTRAZENECA : JP Morgan keeps its Buy rating
05/25French health body backs new COVID vaccine booster campaign for this autumn
05/24Indian vaccine giant Serum plans African plant in global expansion
05/24Danske Bank Initiates Coverage on AstraZeneca With Buy Rating
05/24Vaxzevria approved in the EU as third dose booster against COVID-19
05/24AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 43 665 M - -
Net income 2022 5 151 M - -
Net Debt 2022 23 311 M - -
P/E ratio 2022 40,4x
Yield 2022 2,21%
Capitalization 207 B 207 B -
EV / Sales 2022 5,27x
EV / Sales 2023 4,84x
Nbr of Employees 83 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 26
Last Close Price 133,47 $
Average target price 143,66 $
Spread / Average Target 7,64%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC21.92%205 677
JOHNSON & JOHNSON5.86%472 231
PFIZER, INC.-8.70%302 932
ROCHE HOLDING AG-12.16%282 336
ABBVIE INC.10.78%266 074